Methylprednisolone sodium succinate (Hospira)

País: Nova Zelândia

Língua: inglês

Origem: Medsafe (Medicines Safety Authority)

Ingredientes ativos:

Methylprednisolone sodium succinate 1326mg equivalent to 1000 mg Methylprednisolone;  

Disponível em:

Pfizer New Zealand Limited

DCI (Denominação Comum Internacional):

Methylprednisolone sodium succinate 1326 mg (Equiv to 1000 mg Methylprednisolone)

Dosagem:

1000 mg

Forma farmacêutica:

Powder for injection

Composição:

Active: Methylprednisolone sodium succinate 1326mg equivalent to 1000 mg Methylprednisolone   Excipient: Dibasic sodium phosphate Monobasic sodium phosphate

Unidades em pacote:

Vial, glass, Powder, 1000 mg

Classe:

Prescription

Tipo de prescrição:

Prescription

Fabricado por:

Sicor (Societa Italiana Corticosteroidi) Srl

Resumo do produto:

Package - Contents - Shelf Life: Vial, glass, Powder - 1000 mg - 24 months from date of manufacture stored at or below 25°C

Data de autorização:

1990-07-02

Características técnicas

Data Sheet – New Zealand 

Hosp 2 
                 1 

METHYLPREDNISOLONE SODIUM SUCCINATE POWDER 
FOR INJECTION 
PRESENTATION 
Methylprednisolone Sodium Succinate Powder for Injection is a
sterile lyophilised powder for injection 
containing 500 mg or 1000 mg of Methylprednisolone as the
sodium succinate.  It also contains 6.4 mg 
sodium acid phosphate and 69.8 mg sodium phosphate or 12.8 mg sodium
acid phosphate and 139.6 mg 
sodium phosphate. 

USES  
_ACTIONS _
Methylprednisolone in the form of
methylprednisolone sodium succinate is a potent synthetic 
corticosteroid.  Its anti-inflammatory potency is greater than
prednisolone in the ratio of 5 to 4.  It has only 
minimal mineralocorticoid properties and has less tendency
than prednisolone to induce sodium and 
water retention.  It influences carbohydrate, protein, fat and
purine metabolism, electrolyte and water 
balance, and the functional capacities of the
cardiovascular system, the kidney, the skeletal muscle, 
nervous system and other organs and tissues.  It exerts a
suppressive effect on the immune response. 

_PHARMACOKINETICS _
Methylprednisolone sodium succinate for injection, is rapidly and
extensively hydrolysed _in vivo _by 
cholinesterases to free methylprednisolone. 

_INDICATIONS _
Methylprednisolone sodium succinate may be used in conditions in
which a rapid, intense glucocorticoid 
effect is required. 

ENDOCRINE DISORDERS 
•  Primary or secondary adrenocortical
insufficiency (hydrocortisone or cortisone is the drug of choice; 
synthetic analogs may be used in conjunction with
mineralocorticoids where applicable; in infancy, 
mineralocorticoid supplementation is of particular importance). 
•  Acute adrenocortical insufficiency (hydrocortisone
or cortisone is the drug of choice; mineralocorticoid 
supplementation may be necessary, particularly when synthetic an